Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma

Molecular Cell

Volumn 50, Issue 2, 2013, Pages 185-199

  Snyder, Eric L ^a,b   Watanabe, Hideo ^c,d   Magendantz, Margaret ^a   Hoersch, Sebastian ^a   Chen, Tiffany A ^a   Wang, Diana G ^a   Crowley, Denise ^a   Whittaker, Charles A ^a   Meyerson, Matthew ^c,d,e   Kimura, Shioko ^f   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; HIGH MOBILITY GROUP A2 PROTEIN; MUCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2 1; UNCLASSIFIED DRUG;

ALLELE; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FATE; CELL PROLIFERATION; EPIGENETICS; LATENT PERIOD; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MORPHOLOGY; MOUSE; NONHUMAN; ONCOGENE K RAS; PROTEIN BINDING; PROTEIN EXPRESSION; STOMACH EPITHELIUM; TISSUE DIFFERENTIATION;

ADENOCARCINOMA; ANIMALS; BINDING SITES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; HYPERPLASIA; LUNG; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; NUCLEAR PROTEINS; ORGAN SPECIFICITY; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS P21(RAS); PULMONARY ALVEOLI; RESPIRATORY MUCOSA; STOMACH; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TUMOR BURDEN;

MURINAE;

EID: 84876835924     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.02.018     Document Type: Article

References (67)

1. Abate-Shen C., Shen M.M., Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008, 76:717-727.
2. Barletta J.A., Perner S., Iafrate A.J., Yeap B.Y., Weir B.A., Johnson L.A., Johnson B.E., Meyerson M., Rubin M.A., Travis W.D., et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J. Cell. Mol. Med. 2009, 13(8B):1977-1986.
3. Berghmans T., Paesmans M., Mascaux C., Martin B., Meert A.P., Haller A., Lafitte J.J., Sculier J.P. Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann. Oncol. 2006, 17:1673-1676.
4. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin. Sci. 2009, 116:27-35.
5. Bonzo J.A., Ferry C.H., Matsubara T., Kim J.H., Gonzalez F.J. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J. Biol. Chem. 2012, 287:7345-7356.
6. Cattin A.L., Le Beyec J., Barreau F., Saint-Just S., Houllier A., Gonzalez F.J., Robine S., Pinçon-Raymond M., Cardot P., Lacasa M., Ribeiro A. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol. Cell. Biol. 2009, 29:6294-6308.
7. Chen G., Korfhagen T.R., Xu Y., Kitzmiller J., Wert S.E., Maeda Y., Gregorieff A., Clevers H., Whitsett J.A. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J. Clin. Invest. 2009, 119:2914-2924.
8. Chlabicz M., Gacko M., Worowska A., Lapiński R. Cathepsin E (EC 3.4.23.34)-a review. Folia Histochem. Cytobiol. 2011, 49:547-557.
9. Costa R.H., Kalinichenko V.V., Lim L. Transcription factors in mouse lung development and function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L823-L838.
10. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 2010, 107:21931-21936.
11. Darsigny M., Babeu J.P., Seidman E.G., Gendron F.P., Levy E., Carrier J., Perreault N., Boudreau F. Hepatocyte nuclear factor-4alpha promotes gut neoplasia in mice and protects against the production of reactive oxygen species. Cancer Res. 2010, 70:9423-9433.
12. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 2009, 4:1064-1072.
13. Finberg K.E., Sequist L.V., Joshi V.A., Muzikansky A., Miller J.M., Han M., Beheshti J., Chirieac L.R., Mark E.J., Iafrate A.J. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J. Mol. Diagn. 2007, 9:320-326.
14. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
15. Gao N., LeLay J., Vatamaniuk M.Z., Rieck S., Friedman J.R., Kaestner K.H. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 2008, 22:3435-3448.
16. Garfield D. Can K-ras-mutated atypical adenomatous hyperplasia be another precursor lesion for mucinous bronchioloalveolar carcinoma?. Am. J. Clin. Pathol. 2008, 130:315-316. author reply 316.
17. Hata A., Katakami N., Fujita S., Kaji R., Imai Y., Takahashi Y., Nishimura T., Tomii K., Ishihara K. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J. Thorac. Oncol. 2010, 5:1197-1200.
18. Hatziapostolou M., Polytarchou C., Aggelidou E., Drakaki A., Poultsides G.A., Jaeger S.A., Ogata H., Karin M., Struhl K., Hadzopoulou-Cladaras M., Iliopoulos D. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011, 147:1233-1247.
19. Hayhurst G.P., Lee Y.H., Lambert G., Ward J.M., Gonzalez F.J. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 2001, 21:1393-1403.
20. Hoffman B.G., Robertson G., Zavaglia B., Beach M., Cullum R., Lee S., Soukhatcheva G., Li L., Wederell E.D., Thiessen N., et al. Locus co-occupancy, nucleosome positioning, and H3K4me1 regulate the functionality of FOXA2-, HNF4A-, and PDX1-bound loci in islets and liver. Genome Res. 2010, 20:1037-1051.
21. Homminga I., Pieters R., Langerak A.W., de Rooi J.J., Stubbs A., Verstegen M., Vuerhard M., Buijs-Gladdines J., Kooi C., Klous P., et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011, 19:484-497.
22. Hoshi S., Hoshi N., Okamoto M., Paiz J., Kusakabe T., Ward J.M., Kimura S. Role of NKX2-1 in N-bis(2-hydroxypropyl)-nitrosamine-induced thyroid adenoma in mice. Carcinogenesis 2009, 30:1614-1619.
23. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
24. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
25. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
26. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
27. Kaestner K.H. The FoxA factors in organogenesis and differentiation. Curr. Opin. Genet. Dev. 2010, 20:527-532.
28. Kendall J., Liu Q., Bakleh A., Krasnitz A., Nguyen K.C., Lakshmi B., Gerald W.L., Powers S., Mu D. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc. Natl. Acad. Sci. USA 2007, 104:16663-16668.
29. Kimura S., Hara Y., Pineau T., Fernandez-Salguero P., Fox C.H., Ward J.M., Gonzalez F.J. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996, 10:60-69.
30. Kunii R., Jiang S., Hasegawa G., Yamamoto T., Umezu H., Watanabe T., Tsuchida M., Hashimoto T., Hamakubo T., Kodama T., et al. The predominant expression of hepatocyte nuclear factor 4α (HNF4α) in thyroid transcription factor-1 (TTF-1)-negative pulmonary adenocarcinoma. Histopathology 2011, 58:467-476.
31. Kusakabe T., Kawaguchi A., Hoshi N., Kawaguchi R., Hoshi S., Kimura S. Thyroid-specific enhancer-binding protein/NKX2.1 is required for the maintenance of ordered architecture and function of the differentiated thyroid. Mol. Endocrinol. 2006, 20:1796-1809.
32. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., Lee J., Choi Y.L., Sato M., Wang P., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27:3635-3640.
33. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
34. Maeda Y., Chen G., Xu Y., Haitchi H.M., Du L., Keiser A.R., Howarth P.H., Davies D.E., Holgate S.T., Whitsett J.A. Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation. Am. J. Respir. Crit. Care Med. 2011, 184:421-429.
35. Maeda Y., Tsuchiya T., Hao H., Tompkins D.H., Xu Y., Mucenski M.L., Du L., Keiser A.R., Fukazawa T., Naomoto Y., et al. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J. Clin. Invest. 2012, 122:4388-4400.
36. Menheniott T.R., Peterson A.J., O'Connor L., Lee K.S., Kalantzis A., Kondova I., Bontrop R.E., Bell K.M., Giraud A.S. A novel gastrokine, Gkn3, marks gastric atrophy and shows evidence of adaptive gene loss in humans. Gastroenterology 2010, 138:1823-1835.
37. Minoo P., Su G., Drum H., Bringas P., Kimura S. Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev. Biol. 1999, 209:60-71.
38. Minoo P., Hu L., Xing Y., Zhu N.L., Chen H., Li M., Borok Z., Li C. Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Mol. Cell. Biol. 2007, 27:2155-2165.
39. Offield M.F., Jetton T.L., Labosky P.A., Ray M., Stein R.W., Magnuson M.A., Hogan B.L., Wright C.V. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 1996, 122:983-995.
40. Oien K.A., McGregor F., Butler S., Ferrier R.K., Downie I., Bryce S., Burns S., Keith W.N. Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. J. Pathol. 2004, 203:789-797.
41. Prasad N.B., Biankin A.V., Fukushima N., Maitra A., Dhara S., Elkahloun A.G., Hruban R.H., Goggins M., Leach S.D. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005, 65:1619-1626.
42. Rada-Iglesias A., Bajpai R., Swigut T., Brugmann S.A., Flynn R.A., Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
43. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011, 6:1496-1504.
44. Santangelo L., Marchetti A., Cicchini C., Conigliaro A., Conti B., Mancone C., Bonzo J.A., Gonzalez F.J., Alonzi T., Amicone L., Tripodi M. The stable repression of mesenchymal program is required for hepatocyte identity: a novel role for hepatocyte nuclear factor 4α. Hepatology 2011, 53:2063-2074.
45. Scanlan M.J., Ritter G., Yin B.W., Williams C., Cohen L.S., Coplan K.A., Fortunato S.R., Frosina D., Lee S.Y., Murray A.E., et al. Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. Cancer Immun. 2006, 6:2.
46. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
47. Shen Y., Yue F., McCleary D.F., Ye Z., Edsall L., Kuan S., Wagner U., Dixon J., Lee L., Lobanenkov V.V., Ren B. A map of the cis-regulatory sequences in the mouse genome. Nature 2012, 488:116-120.
48. Stenhouse G., Fyfe N., King G., Chapman A., Kerr K.M. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J. Clin. Pathol. 2004, 57:383-387.
49. Tagne J.-B., Gupta S., Gower A.C., Shen S.S., Varma S., Lakshminarayanan M., Cao Y., Spira A., Volkert T.L., Ramirez M.I. Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors. PLoS ONE 2012, 7:e29907.
50. Tanaka T., Jiang S., Hotta H., Takano K., Iwanari H., Sumi K., Daigo K., Ohashi R., Sugai M., Ikegame C., et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J. Pathol. 2006, 208:662-672.
51. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., Shimada Y., Osada H., Kosaka T., Matsubara H., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007, 67:6007-6011.
52. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., Beer D.G., Powell C.A., Riely G.J., Van Schil P.E., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6:244-285.
53. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
54. Wamstad J.A., Alexander J.M., Truty R.M., Shrikumar A., Li F., Eilertson K.E., Ding H., Wylie J.N., Pico A.R., Capra J.A., et al. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. Cell 2012, 151:206-220.
55. Wan H., Dingle S., Xu Y., Besnard V., Kaestner K.H., Ang S.L., Wert S., Stahlman M.T., Whitsett J.A. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. J. Biol. Chem. 2005, 280:13809-13816.
56. Watanabe H., Francis J.M., Woo M.S., Etemad B., Lin W., Fries D.F., Peng S., Snyder E.L., Tata P.R., Izzo F., et al. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013, 27:197-210.
57. Wederell E.D., Bilenky M., Cullum R., Thiessen N., Dagpinar M., Delaney A., Varhol R., Zhao Y., Zeng T., Bernier B., et al. Global analysis of in vivo Foxa2-binding sites in mouse adult liver using massively parallel sequencing. Nucleic Acids Res. 2008, 36:4549-4564.
58. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
59. Winslow M.M., Dayton T.L., Verhaak R.G., Kim-Kiselak C., Snyder E.L., Feldser D.M., Hubbard D.D., DuPage M.J., Whittaker C.A., Hoersch S., et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011, 473:101-104.
60. Wontakal S.N., Guo X., Smith C., MacCarthy T., Bresnick E.H., Bergman A., Snyder M.P., Weissman S.M., Zheng D., Skoultchi A.I. A core erythroid transcriptional network is repressed by a master regulator of myelo-lymphoid differentiation. Proc. Natl. Acad. Sci. USA 2012, 109:3832-3837.
61. Yamaguchi T., Yanagisawa K., Sugiyama R., Hosono Y., Shimada Y., Arima C., Kato S., Tomida S., Suzuki M., Osada H., Takahashi T. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012, 21:348-361.
62. Yoshizawa A., Motoi N., Riely G.J., Sima C.S., Gerald W.L., Kris M.G., Park B.J., Rusch V.W., Travis W.D. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod. Pathol. 2011, 24:653-664.
63. Young N.P., Crowley D., Jacks T. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 2011, 71:4040-4047.
64. Yu C., Zhang Z., Liao W., Zhao X., Liu L., Wu Y., Liu Z., Li Y., Zhong Y., Chen K., et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis 2012, 33:678-686.
65. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 2003, 3:592-600.
66. Zentner G.E., Tesar P.J., Scacheri P.C. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 2011, 21:1273-1283.
67. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 2011, 12:7-18.